bluebird presents long-term data from CALD gene therapy

bluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy (CALD), showing that it continues to work in the long-te

Novartis points to Zolgensma long-term benefits amid data sc...

Merck & Co in pole position for Ebola vaccine approval as FD...

The FDA is to review Merck & Co’s Ebola vaccine, giving the US pharma a chance to grab a first approval within six months.

Roche's Gazyva wins Breakthrough Therapy status for lupus ne...

Roche’s Gazyva has won Breakthrough Therapy status for its potential new use in the autoimmune disease lupus nephritis, as the Swiss pharma attempts to breathe new life into the drug curren

Acceleron axes clinical development of muscular dystrophy dr...

Acceleron has axed clinical development of its ACE-083 in the inherited muscle-wasting disease muscular dystrophy, after the drug fell short against efficacy measures in a phase 2 trial.

Novartis' Cosentyx heads for fourth indication

Novartis’ Cosentyx could be heading for a fourth indication after the company published late-stage trial data showing it improved symptoms in patients with non-radiographic axial spondyloar